Development of a Universal T Cell Vaccine

Development of a Universal T Cell Vaccine

Bibliografske podrobnosti
Main Authors:	Rosario, M, Letourneau, S, Im, E, Yang, H, Dorrell, L, Korber, B, McMichael, A, Hanke, T
Format:	Conference item
Izdano:	2008

Podobne knjige/članki

Design and pre-clinical evaluation of a universal HIV-1 vaccine.
od: Létourneau, S, et al.
Izdano: (2007)

The 2nd generation of a T-cell vaccine against HIV based on conserved region mosaics
od: Ondondo, B, et al.
Izdano: (2014)

Comment on clinical development of candidate HIV vaccines: different problems for different vaccines.
od: McMichael, A, et al.
Izdano: (2014)

Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses.
od: Estcourt, M, et al.
Izdano: (2005)

Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: One Year Follow On and Epitope Mapping
od: Borthwick, N, et al.
Izdano: (2013)

pTHr.HIVA and MVA.HIVA vaccines (gag p24/p17) augment CD4+T cell responses in chronically infected HIV-1 patients on HAART
od: Ondondo, B, et al.
Izdano: (2005)

Erratum: Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction (Journal of General Virology (2007) vol. 88 ( 1) (1-12))
od: Hanke, T, et al.
Izdano: (2008)

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
od: Hanke, T, et al.
Izdano: (2007)

HIV T cell vaccines, the importance of clades.
od: McMichael, A, et al.
Izdano: (2002)

The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
od: McMichael, A, et al.
Izdano: (2002)

Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS.
od: Hanke, T, et al.
Izdano: (1999)

Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: Mapping of CD8+ T Cell Epitopes.
od: Borthwick, N, et al.
Izdano: (2014)

Design and tests of an HIV vaccine.
od: McMichael, A, et al.
Izdano: (2002)

The HIVconsv Vaccines Induce Polyfunctional and Highly Proliferative T Cells that Control In Vitro HIV Replication: HIV-CORE002 Phase-I Clinical Trial
od: Ondondo, B, et al.
Izdano: (2013)

Interleukin-10 responses to therapeutic vaccination during highly active antiretroviral therapy and after analytical therapy interruption.
od: Yang, H, et al.
Izdano: (2009)

Is an HIV vaccine possible?
od: Mcmichael, A, et al.
Izdano: (1999)

HIV vaccines 1983-2003.
od: Mcmichael, A, et al.
Izdano: (2003)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
od: Borthwick, N, et al.
Izdano: (2012)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and ChAdV-63 in a phase I/IIa clinical trial
od: Hanke, T, et al.
Izdano: (2012)

Altered primary CD8+ T cell response to a modified virus Ankara(MVA)-vectored vaccine in the absence of CD4+ T cell help.
od: Estcourt, M, et al.
Izdano: (2005)

Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy.
od: Yang, H, et al.
Izdano: (2007)

Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques.
od: Im, E, et al.
Izdano: (2006)

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.
od: Borthwick, N, et al.
Izdano: (2014)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
od: Howles, S, et al.
Izdano: (2010)

Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges.
od: Im, E, et al.
Izdano: (2011)

Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference.
od: Larke, N, et al.
Izdano: (2007)

The immune response to HIV
od: McMichael, A, et al.
Izdano: (2009)

A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques.
od: Wee, E, et al.
Izdano: (2002)

Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya.
od: Hanke, T, et al.
Izdano: (2000)

DNA vaccines against human immunodeficiency virus type 1.
od: Estcourt, M, et al.
Izdano: (2004)

MVA as a vector for vaccines against HIV-1.
od: Im, E, et al.
Izdano: (2004)

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1
od: Borthwick, N, et al.
Izdano: (2014)

HIV-host interactions: implications for vaccine design
od: Haynes, B, et al.
Izdano: (2016)

DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice.
od: Hanke, T, et al.
Izdano: (1998)

Is a human CD8 T-cell vaccine possible, and if so, what would it take? Could a CD8+ T-cell vaccine prevent persistent HIV infection?
od: McMichael, A
Izdano: (2017)

Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens
od: Moyo, N, et al.
Izdano: (2017)

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1
od: Ahmed, T, et al.
Izdano: (2012)

Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses
od: Hancock, G, et al.
Izdano: (2015)

Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines.
od: Mwau, M, et al.
Izdano: (2002)

Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.
od: Dorrell, L, et al.
Izdano: (2006)